Youtor
Glympse Bio Diagnostic Technology
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=N4sUOi_NMCg
Dr. Tram Tran, the Chief Medical Officer of Glympse Bio, is working on biosensor technology that can detect and monitor disease by measuring protease activity in a blood sample. Recently published data shows that Glympse's platform can be used to sensitively detect hepatocellular carcinoma, a common type of liver cancer. This is the first time the platform has been used outside of NASH, its lead indication. • • Recently published data shows that Glympse's platform, developed by the Chief Medical Officer of Glympse Bio, Dr. Tram Tran, can sensitively detect hepatocellular carcinoma, a common type of liver cancer, using biosensor technology that measures protease activity in a blood sample. This marks the first time the platform has been applied outside of NASH, its lead indication. • • Recently published data shows Glympse's platform can detect hepatocellular carcinoma, a common type of liver cancer, using biosensor technology and blood sample protease activity. This is the first time the platform has been used outside of NASH, its lead indication. Dr. Tram Tran, the Chief Medical Officer of Glympse Bio, developed the platform. • • #GlympseBio • • Tram Tran is a liver and viral expert with over 20 years of experience. She previously worked at Gilead Sciences, where she was responsible for liver diseases, fibrosis, and COVID-19. Before that, she was the Medical Director of Liver Transplantation and GI Fellowship Program Director at Cedars-Sinai Medical Center and a Professor of Medicine
#############################
